Case Report

Chronic pulmonary aspergillosis – chronic cavitary pulmonary aspergillosis: a case report

Francis Celeste , Ency Eveline

Francis Celeste
General Practitioner Siloam Hospitals Kebon Jeruk, Jakarta-Indonesia. Email: francisceleste3@outlook.com

Ency Eveline
General Practitioner, Mochtar Riady Comprehensive Cancer Center (MRCCC), Jakarta-Indonesia
Online First: August 01, 2020 | Cite this Article
Celeste, F., Eveline, E. 2020. Chronic pulmonary aspergillosis – chronic cavitary pulmonary aspergillosis: a case report. Intisari Sains Medis 11(2): 481-483. DOI:10.15562/ism.v11i2.614


Background: Chronic pulmonary aspergillosis (CPA) includes several disease manifestations. Almost all cases of CPA are caused by A. fumigatus. There are several underlying diseases that predispose patients to CPA. Treatment is often individualised depending on underlying disease process and the patient’s pulmonary status.

Case presentation: A 57-year-old male with a history of renal transplant in the year 2006, routine on immunosuppressants, pulmonary tuberculosis relapse on anti-tuberculosis medications, aspergillosis on long term voriconazole, and DM type 2 presented with dyspnea, massive hemoptysis and productive cough 3 months before admission. Patient was diagnosed with aspergillosis in October 2012 through bronchoscopy. Microbiology result showed Aspergillus flavus. Enhanced thoracal CT result showed a cavitating nodule with soft tissue lesion in upper right lung, with fibrotic changes in the right lung and mild tubular bronchiectasis, with bilateral pleural thickening. Patient was then planned for lung resection due to the persistent pulmonary cavity. However, his clinical condition worsened and the patient passed away a few days before surgery.

Conclusion: Diagnosing chronic pulmonary aspergillosis can often be challenging. The diagnosis of CPA can be inferred from a single chest radiograph. Despite this, detailed and sequentially acquired radiographic data may be required to observe both the typical radiographic features and the very slow progression of this disease. Treatment is often individualised. Azoles are the antifungal drug of choice when required.

References

References

Graham KG, Nasir A. Chronic cavitary pulmonary aspergillosis: a case report and review of the literature. Am J Case Rep. 2019;20:1220-1224.

Izumikawa K. Recent advance in chronic pulmonary aspergillosis. Respir Investig. 2016;54(2):85-91.

Denning D, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, Ullmann A, Dimopoulos G. and Lange C. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47(1):45-68.

Maghrabi F, Denning DW. The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach. Curr Fungal Infect Rep. 2017;11(4):242-251.

Kosmidis C, Denning W. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70(3):270-7.


No Supplementary Material available for this article.
Article Views      : 20
PDF Downloads : 9